Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.

Webster LR, Kinzler ER, Pantaleon C, Iverson M, Aigner S.

Adv Ther. 2019 May 7. doi: 10.1007/s12325-019-00963-0. [Epub ahead of print]

PMID:
31065992
2.

Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Zebala JA, Searle SL, Webster LR, Johnson MS, Schuler AD, Maeda DY, Kahn SJ.

J Pain. 2019 Apr 18. pii: S1526-5900(18)30815-0. doi: 10.1016/j.jpain.2019.04.005. [Epub ahead of print]

3.

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW.

Postgrad Med. 2019 Apr;131(3):225-229. doi: 10.1080/00325481.2019.1585688. Epub 2019 Mar 19.

PMID:
30794760
4.

Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study.

Bass A, Webster LR, Matschke KT, Malhotra BK, Wolfram G.

Ther Adv Drug Saf. 2019 Feb 1;10:2042098618821274. doi: 10.1177/2042098618821274. eCollection 2019.

5.

A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.

Friedmann N, Marsman MR, de Kater AW, Burns LH, Webster LR.

J Opioid Manag. 2018 Nov/Dec;14(6):437-443. doi: 10.5055/jom.2018.0476.

PMID:
30629280
6.

Uncritical Publication of a Biased Study Leads to Misleading Media Reports.

Webster LR.

Pain Med. 2018 Nov 20. doi: 10.1093/pm/pny234. [Epub ahead of print] No abstract available.

PMID:
30462306
7.
8.

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.

Webster LR, Israel RJ.

J Pain Res. 2018 Aug 13;11:1503-1510. doi: 10.2147/JPR.S160488. eCollection 2018.

9.

Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.

Webster LR, Brewer RP, Lichtlen P, Losch-Beridon T, Mareya S, Wang M.

Pain Med. 2018 Jun 1;19(6):1195-1205. doi: 10.1093/pm/pnx212.

PMID:
29897589
10.

Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.

Webster LR, Pantaleon C, Iverson M, Smith MD, Kinzler ER, Aigner S.

Pain Res Manag. 2018 Apr 23;2018:7276021. doi: 10.1155/2018/7276021. eCollection 2018.

11.

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.

Webster LR, Iverson M, Pantaleon C, Smith MD, Kinzler ER, Aigner S.

Pain Med. 2019 Apr 1;20(4):747-757. doi: 10.1093/pm/pny043.

12.

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study.

Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC.

Pain. 2018 May;159(5):987-994. doi: 10.1097/j.pain.0000000000001174.

13.

Loss of Trust and Empathy Ends an Era of Opioid Self-Assessment.

Webster LR.

Pain Med. 2018 Feb 5. doi: 10.1093/pm/pny010. [Epub ahead of print] No abstract available.

PMID:
29415168
14.

Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.

Webster LR, Viscusi ER, Brown C, Dayno JM.

Curr Med Res Opin. 2018 May;34(5):893-901. doi: 10.1080/03007995.2018.1433144. Epub 2018 Feb 8.

PMID:
29368961
15.

Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history.

Rockett IRH, Caine ED, Connery HS, D'Onofrio G, Gunnell DJ, Miller TR, Nolte KB, Kaplan MS, Kapusta ND, Lilly CL, Nelson LS, Putnam SL, Stack S, Värnik P, Webster LR, Jia H.

PLoS One. 2018 Jan 10;13(1):e0190200. doi: 10.1371/journal.pone.0190200. eCollection 2018.

16.

Interpreting labels of abuse-deterrent opioid analgesics.

Webster LR.

J Opioid Manag. 2017 Nov/Dec;13(6):415-423. doi: 10.5055/jom.2017.0418. Review.

PMID:
29308588
17.

Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.

Miller CJ, Dart RC, Katz NP, Webster LR.

J Opioid Manag. 2017 Nov/Dec;13(6):379-389. doi: 10.5055/jom.2017.0416. Review.

PMID:
29308585
18.

Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.

Argoff CE, Alford DP, Fudin J, Adler JA, Bair MJ, Dart RC, Gandolfi R, McCarberg BH, Stanos SP, Gudin JA, Polomano RC, Webster LR.

Pain Med. 2018 Jan 1;19(1):97-117. doi: 10.1093/pm/pnx285.

19.

Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users.

Mickle TC, Guenther SM, Barrett AC, Roupe KA, Zhou J, Dickerson D, Webster LR.

Pain Med. 2018 Dec 1;19(12):2438-2449. doi: 10.1093/pm/pnx247.

20.

Risk Factors for Opioid-Use Disorder and Overdose.

Webster LR.

Anesth Analg. 2017 Nov;125(5):1741-1748. doi: 10.1213/ANE.0000000000002496. Review.

PMID:
29049118
21.

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.

Bond M, Schoedel KA, Rabinovich-Guilatt L, Gasior M, Tracewell W, Malamut R, Ma Y, Webster LR.

Pain Med. 2018 Aug 1;19(8):1597-1612. doi: 10.1093/pm/pnx133.

22.
23.

Opioid-sparing Effects of SoluMatrix Indomethacin in a Phase 3 Study in Patients With Acute Postoperative Pain.

Gharibo CG, Argoff C, Markenson JA, Webster LR, Nezzer J, Solorio D, Lauterio M, Young C.

Clin J Pain. 2018 Feb;34(2):138-144. doi: 10.1097/AJP.0000000000000525.

PMID:
28591082
25.

Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.

Webster LR, Markman J, Cone EJ, Niebler G.

Postgrad Med. 2017 Jan;129(1):102-110. doi: 10.1080/00325481.2017.1268902. Epub 2016 Dec 12. Review. Erratum in: Postgrad Med. 2017 May;129(4):491.

PMID:
27915497
26.

Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users.

Webster LR, Smith MD, Lawler J, Lindhardt K, Dayno JM.

PM R. 2016 Sep;8(9S):S300-S301. doi: 10.1016/j.pmrj.2016.07.352. Epub 2016 Sep 24. No abstract available.

PMID:
27673177
27.

Poster 420 Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users.

Smith MD, Webster LR, Lawler J, Lindhardt K, Dayno JM.

PM R. 2016 Sep;8(9S):S298. doi: 10.1016/j.pmrj.2016.07.345. Epub 2016 Sep 24. No abstract available.

PMID:
27673172
29.

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.

Webster LR, Pantaleon C, Shah MS, DiFalco R, Iverson M, Smith MD, Kinzler ER, Aigner S.

Pain Med. 2017 Jul 1;18(7):1303-1313. doi: 10.1093/pm/pnw213.

PMID:
27651506
31.

Pharmacogenetics and Personalized Medicine in Pain Management.

Webster LR, Belfer I.

Clin Lab Med. 2016 Sep;36(3):493-506. doi: 10.1016/j.cll.2016.05.007. Epub 2016 Jun 22. Review.

PMID:
27514464
32.

Mitigation Strategies for Opioid Abuse.

Webster LR.

N Engl J Med. 2016 Jul 7;375(1):95-6. doi: 10.1056/NEJMc1605652. No abstract available.

PMID:
27406369
33.

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.

Webster LR, Camilleri M, Finn A.

Subst Abuse Rehabil. 2016 Jun 14;7:81-6. doi: 10.2147/SAR.S100998. eCollection 2016. Review.

34.
35.

Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.

Backonja M, Webster LR, Setnik B, Bass A, Sommerville KW, Matschke K, Malhotra BK, Wolfram G.

Am J Drug Alcohol Abuse. 2016 Sep;42(5):539-549. Epub 2016 May 21.

PMID:
27211522
36.

Chronic Pain and the Opioid Conundrum.

Webster LR.

Anesthesiol Clin. 2016 Jun;34(2):341-55. doi: 10.1016/j.anclin.2016.01.002. Review.

PMID:
27208714
37.

Correction: EPR detection and characterisation of a paramagnetic Mo(iii) dihydride intermediate involved in electrocatalytic hydrogen evolution.

Prior C, Webster LR, Ibrahim SK, Wright JA, Alghamdi AF, Oganesyan VS, Pickett CJ.

Dalton Trans. 2016 Apr 28;45(16):7178. doi: 10.1039/c6dt90066f.

PMID:
27067815
38.
39.

EPR detection and characterisation of a paramagnetic Mo(iii) dihydride intermediate involved in electrocatalytic hydrogen evolution.

Prior C, Webster LR, Ibrahim SK, Wright JA, Alghamdi AF, Oganesyan VS, Pickett CJ.

Dalton Trans. 2016 Feb 14;45(6):2399-403. doi: 10.1039/c5dt04432d. Epub 2016 Jan 14. Erratum in: Dalton Trans. 2016 Apr 28;45(16):7178.

PMID:
26763207
40.

Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials.

Setnik B, Pixton GC, Webster LR.

Curr Med Res Opin. 2016;32(3):563-72. doi: 10.1185/03007995.2015.1131153. Epub 2016 Jan 26.

PMID:
26695349
41.

Opioid abuse-deterrent strategies: role of clinicians in acute pain management.

Webster LR, Brennan MJ, Kwong LM, Levandowski R, Gudin JA.

Postgrad Med. 2016 Jan;128(1):76-84. doi: 10.1080/00325481.2016.1113841. Epub 2015 Dec 3. Review.

PMID:
26631936
42.

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine.

Webster LR, Smith MD, Unal C, Finn A.

J Pain Res. 2015 Nov 4;8:791-8. doi: 10.2147/JPR.S90780. eCollection 2015.

43.

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain.

Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP.

J Pain Res. 2015 Oct 30;8:771-80. doi: 10.2147/JPR.S88203. eCollection 2015. Erratum in: J Pain Res. 2018 Jun 19;11:1163.

44.

Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation.

Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR.

Pain Med. 2015 Dec;16(12):2324-37. doi: 10.1111/pme.12937. Epub 2015 Nov 19. Review.

45.

Current Regulations Related to Opioid Prescribing.

Webster LR, Grabois M.

PM R. 2015 Nov;7(11 Suppl):S236-S247. doi: 10.1016/j.pmrj.2015.08.011. Review.

PMID:
26568503
46.

Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies.

Cheatle MD, Webster LR.

Pain Med. 2015 Oct;16 Suppl 1:S22-6. doi: 10.1111/pme.12910. Review.

47.

Opioid-Induced Constipation.

Webster LR.

Pain Med. 2015 Oct;16 Suppl 1:S16-21. doi: 10.1111/pme.12911. Review.

PMID:
26461071
48.

A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.

Jamal MM, Adams AB, Jansen JP, Webster LR.

Am J Gastroenterol. 2015 May;110(5):725-32. doi: 10.1038/ajg.2015.106. Epub 2015 Apr 28.

49.

A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study.

Carlquist JF, Moody DE, Knight S, Johnson EG, Fang WB, Huntinghouse JA, Rollo JS, Webster LR, Anderson JL.

Mol Diagn Ther. 2015 Apr;19(2):131-8. doi: 10.1007/s40291-015-0137-4.

PMID:
25903311
50.

The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Schatman ME, Webster LR.

J Pain Res. 2015 Mar 18;8:153-8. doi: 10.2147/JPR.S83368. eCollection 2015. No abstract available.

Supplemental Content

Loading ...
Support Center